Treatment of Reactive Arthritis in Chlamydia trachomatis Genitourinary Infection
Clinical Scenario
Reactive arthritis (ReA) presenting in the context of a Chlamydia trachomatis genitourinary infection. Chlamydia trachomatis is the most common causative agent in genitourinary-triggered ReA, distinguishing this presentation from the gastroenteric forms associated with organisms such as Shigella, Salmonella, Yersinia, and Campylobacter.
Treatment Approach
Long-term antibiotic monotherapy is not recommended given the available evidence. The protocol for this scenario involves a structured combination antibiotic regimen — the specific agents, sequencing, and duration are set out in the full evidence-based protocol.
Treatment Goals
Complete resolution of clinical manifestations, normalisation of inflammatory markers, and no recurrence of arthritis at 6 months.
References
- The most common agent triggering ReA after a genitourinary infection is Chlamydia trachomatis, whereas Shigella, Salmonella, Yersinia and Campylobacter are the most common involved agents in gastroenteric-associated disease.
- Consequently, the role of antibiotic treatment is actually uncertain, but since the majority of the trials demonstrated a lack of efficacy, long-term antibiotic monotherapy is not recommended.
- Chronic ReA patients with PCR-proven peripheral blood cells or synovial Chlamydia positivity, which is proof of persistent infections, were randomly allocated to three groups, one treated with doxycycline plus rifampin association, one treated with azithromycin plus rifampin association and the last receiving placebo.
- A significant greater clinical response (63% vs. 22%) was observed in combination treatment groups, with 20% of patients achieving complete remission compared to none of the placebo group.
- Complete remission: complete resolution of the clinical manifestation, normalisation of inflammatory markers, no recurrence of the arthritis.
View source ↗